DVS Sciences announces introduction of new products for single cell analysis

NewsGuard 100/100 Score

DVS Sciences, Inc., a privately held innovator of novel multi-parameter single-cell analyzers and reagents for biological research, today announced the introduction of the new CyTOF 2 Mass Cytometer and new MaxPar Panel Kits designed specifically for simultaneous high-parameter single cell analysis.

“With these new products, DVS Sciences will continue to experience unprecedented world-wide growth allowing us to scale our customer support and provide additional resources to our new and existing customers”

The DVS Sciences® CyTOF 2 system leverages the same mass cytometry technology that has been the foundation to the success and world-wide adoption of the CyTOF Mass Cytometer. The technology enables comprehensive functional and phenotypic characterization of complex systems at the single cell level in diverse disciplines including immunology, cancer research, stem cell biology and drug profiling. On a newly designed chassis, the CyTOF 2 system delivers enhanced performance and improved user experience, providing the most powerful cell analysis platform on the market. The CyTOF 2 platform uniquely has the ability to simultaneously measure up to 120 cell biomarkers in single cells at up to 1000 cells per second. DVS Cytobank™, a cloud based analytical software platform, is also available to automatically analyze and manage data sets resulting from the CyTOF platform.

The new MaxPar Panel Kits deliver an integrated research solution for the CyTOF customer. The MaxPar Panel Kits contain all necessary reagents researchers need to carry out high dimensional experiments in a single tube. Five new MaxPar Panel Kits are now available that provide up to 17 ready to use metal-conjugated antibodies and can be combined simultaneously with up to 16 additional antibodies allowing high resolution single cell assays of multiple cell populations in a single tube.

"These new products place DVS Sciences at the cutting edge of life science research by providing the most comprehensive platform available to researchers for high parameter single cell analysis," says Joseph Victor, President & CEO of DVS Sciences. "With these new products, DVS Sciences will continue to experience unprecedented world-wide growth allowing us to scale our customer support and provide additional resources to our new and existing customers," Victor also commented.

Source:

DVS Sciences, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights how age affects nasal cell response to SARS-CoV-2